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Abstract
Background: Bone marrow-derived stromal cells (BMSCs) are important for development, tissue
cell replenishment, and wound healing in physiological and pathological conditions. BMSCs were
found to preferably reach sites undergoing the process of cell proliferation, such as wound and
tumor, suggesting that BMSCs may be used as a vehicle for gene therapy of tumor.
Methods: Mouse BMSCs were loaded with recombinant adenoviruses which express soluble
Vascular Endothelial Growth Factor Receptor-1 (sFlt-1). The anti-angiogenesis of sFlt-1 in BMSCs
was determined using endothelial cells proliferation inhibition assay and alginate encapsulation
assay. The anti-tumor effects of BMSCs expressing sFlt-1 through tail-vein infusion were evaluated
in two mouse tumor metastases models.
Results: BMSCs genetically modified with Adv-GFP-sFlt-1 could effectively express and secret sFlt-
1. BMSCs loaded with sFlt-1 gene could preferentially home to tumor loci and decrease lung
metastases and prolong lifespan in mouse tumor model through inducing anti-angiogenesis and
apoptosis in tumors.
Conclusion: We demonstrated that BMSCs might be employed as a promising vehicle for tumor
gene therapy which can effectively not only improve the concentration of anticancer therapeutics
in tumors, but also modify the tumor microenvironment.
Background
Bone marrow-derived stromal cells (BMSCs), also known
as mesenchymal stem cells or nonhematopoietic progen-
itor cells, are precursors that can be differentiated into
chondrocytes, osteoblasts, adipocytes, neurons and other
cell types [1]. They are important for development and
cell replenishment of active proliferating tissues in physi-
ological conditions, such as blood, skin and gut. In path-
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wound healing and tissue regeneration. In animal and
clinical experiments, BMSCs have been used for tissue
damage repair and functional reconstruction of organs,
such as myocardial infarction, osteogenesis imperfecta,
syndrome of multiple organ failure and rebuilding of
hematopoietic system after chemotherapy of breast cancer
[2-5].
It has been reported that the conditions featured by
enhanced cell proliferation and tissue remodeling, such as
bone fractures, embryo growth and tumorigenesis, offer
an appropriate microenvironment for migration, prolifer-
ation and differentiation of stem cells delivered systemi-
cally [3,6-9]. The formation of tumor stroma is similar to
that of wound healing and results in a microenvironment
which is suitable for the proliferation of bone marrow-
derived stem cells [10]. Therefore, we hypothesize that
systemically delivered BMSCs would preferentially home
to tumor tissues and participate in the formation of tumor
stroma. Therefore, it will be useful to develop a new tar-
geting system based on genetically modified BMSCs for
tumor gene therapy. The feasibility of this approach has
been demonstrated by Matus Studeny's experimemt [11].
Metastasis is the most common and fundamental charac-
teristics of solid tumors. Most deaths of cancerous patients
result from the ruthless growth of metastases that are
resistant to conventional remedies. This urges us to
develop a novel therapeutic strategy for inhibiting tumor
metastasis. The concept that tumor growth and metastasis
relies on angiogenesis has been widely proven and
accepted. The signal axis of vascular endothelial growth
factor (VEGF) and its receptors (VEGFR-1, VEGFR-2 and
VEGFR-3) is involved in the formation and progress of
tumors. The soluble VEGF receptor-1 (sFlt-1) has been
shown to be effective in inhibition of cancerous angiogen-
esis [12].
In this report, we developed a novel strategy of tumor
gene therapy in which BMSCs loaded with recombinant
adenoviruses expressing sFlt-1 could effectively suppress
tumor growth through inhibiting angiogenesis and metas-
tases and prolong the lifespan in mouse model, indicating
that BMSCs might be employed as an effective carrier for
tumor gene therapy.
Methods
BMSCs isolation and culture
BMSCs were isolated from femur bone marrow of male
BALB/c mouse. Mononuclear cells were separated by cen-
trifugation over a Ficoll gradient (Sigma Chemical Co., St.
Louis, MO) of 1.077 g/ml. The cells were cultured in L-
DMEM containing 10% fetal bovine serum (Gibco BRL,
Inc) at an initial seeding density of 1 × 105 cells/cm2 at
37°C with 5% CO2 and 95% humidified atmosphere.
The nonadherent cells were removed and washed with
PBS after 24 hours, and the monolayer of adherent cells
were cultured until they reached to confluence. The cells
were then trypsinized (0.25% trypsin with 0.1% EDTA),
subcultured at densities of 5000–6000 cells/cm2. and used
for experiments during passages five to eight. CD34,
CD29 and CD44 expressions in BMSCs were determined
by flow cytometry. Briefly, the trypsinized BMSCs were
adjusted to 1 × 107cells/ml in media (1% bovine serum
albumin, 0.2% sodium azide in PBS), and then stained
with FITC-conjugated monoclonal antibodies (BD Bio-
sciences, San Jose, CA, USA) on ice according to the man-
ufacturer's protocol, and followed by detection with flow
cytometry.
Production of adenovirus and genetic modification of 
BMSCs
AdenoVec-GFP-sFlt-1 and AdenoVec-GFP (InvivoGen,
San Diego, CA) were transfected into HEK-293 cells using
jetPEI (Qbiogene, Nottingham, UK) according to the
manufacturer's protocol. Seven to 14 days later, the
recombinant adenoviruses were harvested from the cul-
tures and the viruses were further amplified in 293 cells,
and then tittered by plaque assay. BMSCs were infected
with adenoviruses at a multiplicity of infection (MOI) of
3000 for 2 hours followed by replacing the infection
medium. Twenty-four hours later, the virus-infected
BMSCs were harvested for subsequent experiments [11].
Western blot analysis
Western blot analysis was performed as described previ-
ously [13]. Briefly, the secreted proteins in supernatants of
the culture were precipitated by TCA-DOC/acetone and
the western blot assay was performed using standard
method with primary monoclonal antibody of anti-sFlt-1
(1:500 dilution, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and a biotinylated secondary antibody, and the
proteins on the membrane were visualized by Vectastain
ABC kit (Vector Laboratories, Burlingame, CA, USA).
Mouse endothelial cells proliferation inhibition assay
The mouse endothelial cells proliferation inhibition assay
was performed as described previously for examining sup-
pression of sFlt-1 in the conditioned media on VEGF-
driven proliferation of endothelial cells [14]. The condi-
tioned media were obtained from BMSCs infected with
Adv-GFP-sFlt-1, Adv-GFP, or PBS (mock infected), respec-
tively. Endothelial cells were grown in 24-well plates at
37°C in DMEM containing 10% FBS. At 50% confluence,
the cells were washed with PBS after removal of the
DMEM media, and then 0.5 ml of conditioned media was
added. Fifteen minutes later, VEGF was added to each well
with a final concentration of 10 ng/ml and the cells were
incubated at 37°C. After 72 h, the cells were trypsinized,Page 2 of 10
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blue assay.
Alginate encapsulation assay
Alginate-encapsulated tumor cell assays were performed
as described previously [13]. Briefly, tumor cells, BMSCs
expressing sFlt-1 or mixed cells were resuspended in a
1.5% solution of sodium alginate and added dropwise
into a swirling 37°C solution of 250 mM calcium chlo-
ride. Alginate beads were formed with about 1 × 105 cells
per bead. After mice were anesthetized, 4 beads were
implanted subcutaneously into an incision made on the
dorsal side. Incisions were closed with surgical clamps.
After 21 days, mice were injected intravenously with 100
μl of a 100 mg/kg FITC-dextran solution (Sigma). Beads
were surgically removed, and FITC-dextran was quantified
against a standard curve of FITC-dextran.
Murine tumor metastases models and treatment
The colon carcinoma CT26, Lewis lung cancer LLC and
fibrosarcoma MethA cell lines were used in this study.
Metastasis models of LLC and CT26 were generated as
described previously [15]. Briefly, female C57BL/6 and
BALB/c mice were received i.m. injections of 2×105 LLC in
leg or i.v. injection of 2×105 CT26 cells from tail vein in
100 μl of PBS, respectively and then the animals were ran-
domly divided into four groups (10 mice/group). After 4
days for CT26 model and 10 days for LLC model of tumor
inoculation, 1×106 of BMSCs infected with Adv-GFP-sFlt-
1, BMSCs infected with Adv-GFP, unifected BMSCs or 100
μl of 0.9% NaCl solution alone were administered via tail
vein for four doses at 3 days intervals for CT26 model and
5 days intervals for LLC model. Mice received LLC or CT26
injection were sacrificed on day 32 or day 16 after inocu-
lation, respectively, when control mice became mori-
bund, and the lungs from each mouse were removed and
the surface lung metastases (>3 mm) were measured and
scored [15]. The lungs of animals were also fixed in 10%
buffered formalin followed by histological analysis. All of
the mice used in this study were approved by the West
China Hospital Cancer Center's Animal Care and Use
Committee. In the handling and care of animals, all pos-
sible steps were taken to avoid animals' suffering and
efforts were made to use the minimum number of ani-
mals.
Histological analysis
The tissues were fixed in 10% neutral buffered formalin
solution and embedded in paraffin. Sections of 3–5 μm
were stained with hematoxylin and eosin (H.E.). Frozen
sections were fixed in acetone, incubated, and stained
with anti-CD31 antibody, then visualized with DAKO
LSAB kit (DAKO, Carpinteria, CA), as described previ-
ously. Vessel density was determined by counting the
number of microvessels per high-power field in the sec-
tions, as described [16]. Apoptosis in tumor tissues was
determined by terminal dUTP nick-end labeling (TUNEL)
method using an in situ cell death detection kit (Roche
Molecular Biochemicals) following the manufacturer's
protocol [17,18]. Sections in H&E staining and immuno-
histochemical staining were observed by two pathologists
in a blinded manner.
Fluorescent in situ hybridization (FISH)
Fluorescent in situ hybridization was performed accord-
ing to the mouse Y chromosome probe manual
(STAR*FISH; Cambio, Cambridge, England) with some
modifications. Cryostat sections of 5 μm in thickness were
fixed in Carnoy's fixative for three times, 10 min each, and
the sections were incubated in pepsin solution (1% in
0.1N HCl) for 10 minutes and rinsed in PBS. Serial etha-
nol dehydration was done (1.5 min each), and the slides
were air-dried at room temperature. Sections were dena-
tured at 65°C for 2 min in preheated 70% formamide and
2×SSC buffer, pH 7.0, and were then 'quenched' with ice-
cold 70% ethanol for 1.5 min. Serial ethanol dehydration
was done again. The mouse Y chromosome probe labeled
with Cy3 was denatured at 65°C for 10 min and applied
to the sections. The sections were coverslipped and sealed
with rubber cement for incubation overnight in a
hydrated slide box at 37°C. The next day, the coverslips
were carefully removed. The sections were washed twice in
preheated 50% formamide in 2×SSC buffer for 5 min each
at 45°C and were then gently washed twice in preheated
1×SSC buffer for 5 min each at 45°C.
Statistical assay
Significance was determined using one-way ANOVA and
log-rank test (SPSS 11.0 for windows). Difference
between groups were significant at a value of P < 0.05.
Results
BMSCs isolation, genetic modification and sFlt-1 function 
validation
After harvest of monolayer cells with spindle-like mor-
phology from mouse bone marrow, three CD markers
(CD34, CD29 and CD44) were used for characterizing
BMSCs. The cells were positive for CD29, CD44, and neg-
ative for CD34, indicating that they didn't belong to
hematopoietic progenitor cells, but rather bone marrow-
derived stromal cells (BMSCs) or mesenchymal stem cells
(MSCs). BMSCs were cultured to reach to 90% confluence
and incubated with adenoviruses at a MOI of 3000 for 2
hours. Twenty four hours later, all of the cells were GFP-
positive checked by fluorescence microscopy and the cells
were ready for tail vein infusion after PBS washing two
times (Figure 1A). The secreted sFlt-1 in the supernatants
of conditioned media was verified by Western blot (Figure
1B) and the function of sFlt-1 was validated by endothe-
lial cell growth inhibition assay in vitro. The concentratedPage 3 of 10
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Adv-GFP-sFlt-1 or with Adv-GFP were applied to the
mouse endothelial cells grown in 24-well plates, followed
by stimulation with a 10 ng/ml of VEGF 15 minutes later.
Conditioned media from BMSCs infected with Adv-GFP-
sFlt-1 resulted in inhibition of endothelial cells prolifera-
tion by about 50% compared with that from BMSCs
infected with Adv-GFP or uninfected BMSCs (Figure 1C, P
< 0.05), indicating that the BMSCs infected with Adv-GFP-
sFlt-1 could effectively express and secret sFlt-1.
Anti-metastasis effect
The mouse CT26 and LLC metastasis models were used to
determine whether BMSCs expressing sFlt-1 suppress the
growth of metastatic neoplasm. The metastatic nodules >
3 mm were assessed as an indicator of angiogenesis
because the growth of tumors > 3 mm is thought to be vas-
culature sensititive [19]. Most of the mice systemically
administered with control BMSCs or NaCl solution devel-
oped macroscopic lung metastases, whereas mice treated
with BMSCs expressing sFlt-1 decreased lung metastases.
The tumor nodules (> 3 mm) of lung surface were signifi-
cantly decreased in the mice treated with BMSCs express-
ing sFlt-1 (P < 0.05) (Figure 2A, B). Lung weight, which
correlates with total tumor burden, was also reduced sig-
nificantly in the team of mice administered with BMSCs
expressing sFlt-1 (Figure 2C). Booming proliferation of
tumor cells and severe destruction of lung tissues were
observed in the H.E. staining for control mice, whereas in
the mice treated with BMSCs expressing sFlt-1, cancerous
cells were less nourished and lung tissues were relatively
normal (Figure 2D). Benefited from the decrease of tumor
burden in the lung metastases, the lifespan of the tumor-
bearing mice was prolonged significantly (Figure 2E, P <
0.05). The similar results were also observed from mouse
LLC metastasis model (Figure 3).
Inhibition of angiogenesis and induction of apoptosis
Systemically delivered BMSCs which express sFlt-1 were
shown to induce apparent inhibition of angiogenesis in
BMSCs infection and verification of secreted sFlt-1Figure 1
BMSCs infection and verification of secreted sFlt-1. After the BMSCs were confirmed by flow cytometric analysis, 
BMSCs were grown to 90% confluence and infected with adenoviruses at a multiple of infection of 3000 for 2 hours. 24 hours 
later, BMSCs were harvested and ready for use. Fluorescence microscope showed up to 100% GFP-positive cells. (Figure 1-A). 
Supernatants deposits from sFlt-1 bearing BMSCs could be recognized by antibodies reactive to NH2 terminus of mouse Flt-1, 
but negative staining in supernatants deposits from control BMSCs in Western blot analysis. (Figure 1-B). Conditioned media 
from Adv-sFlt-1 infected BMSCs was shown to inhibit the VEGF-driven mouse endothelial cells proliferation by about 50% 
compared with controls (Figure 1-C, P < 0.05).Page 4 of 10
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try. Angiogenesis within tumor tissue was estimated by
counting the number of microvessels on the section stain-
ing with an anti-CD31 antibody. Very few newborn
microvessels were found around the tumor cells in the
BMSCs-sFlt-1 group, whereas abundant microvessels
existed in three controls (Figure 4A, B, P < 0.05). The inhi-
bition of angiogenesis in mice treated with BMSCs
expressing sFlt-1 was further confirmed in alginate encap-
sulation assay. The surface vessel densities and the FITC-
Anti-tumor effect in mouse CT26 colon adenocarcinoma modelFigure 2
Anti-tumor effect in mouse CT26 colon adenocarcinoma model. Female BALB/c mice received i.v. injection of 2×105 
CT26 cells in 100 μl of PBS. Treatment with 1×106 Adv-GFP-sFlt-1 infected BMSCs(, black rhombus), 1×106 Adv-GFP 
infected BMSCs (▪, black quadrilateral), 1×106 uninfected BMSCs (▲, black triangle) and 100 μl of 0.9% NaCl solution alone (●, 
black circularity) were administered i.v. from tail vein. Treatment with sFlt-1-bearing BMSCs could decrease the number of and 
growth of surface metastases (Figure 2-A, D) and abolish the tumor burden by rendering the weight of lungs similar to that of 
normal mice (Figure 2-C). Mean numbers of lung tumor nodules in each group are shown (Figure 2-B). Values are plotted as 
means ± SEM (P < 0.05). The percentage of metastatic foci > 3 mm are marked as solid bars. A significant increase of survival 
rate in sFlt-1-bearing BMSCs treated mice, compared with the controls (Figure 2-E, P < 0.05. By log-rank test), was found in 
the tumor model.Page 5 of 10
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contain relatively high ratio of sFlt-1-bearing BMSCs to
LLC cells (Figure 4C, D, P < 0.05). Furthermore, an
another alginate assay showed that the anti-angiogenesis
effect of local production of sFlt-1 (came from the alginate
beads being filled with sFlt-1-bearing BMSCs and tumor
cells, or the BMSCs intravenous injected) was stronger
than systemic production of sFlt-1 (came from the algi-
nate beads being filled with sFlt-1-bearing BMSCs and
implanted in the distant site) (Figure 4-E and 4F). Being
starved of the nourishment by the inhibition of angiogen-
esis in neoplasm, augmentation of apoptosis of cancerous
cells was detected by the TUNEL assay (Figure 5, P < 0.05).
The inhibition of angiogenesis and the consequent induc-
tion of apoptosis underlie the mechanism of the metas-
tases decrease and the life-span prolongation in tumor-
bearing mice.
Verification of BMSCs' homing to tumor
It has been reported that ubiquitous tissue distribution of
adipose-derived stem cells in normal mouse was observed
when the cells were systematically administrated [20]. We
are concerned about the existence of BMSCs in the metas-
tases and the surrounding tissues. To detect the tumor tro-
pism of BMSCs after systemically administration,
fluorescent in situ hybridization of Y chromosome was
performed on frozen section of CT26 lung metastasis after
BMSCs administration one week. Positive signals were
observed in the frozen section of lung metastases exclu-
sively, whereas the relatively normal area of lung tissue
was totally negative for the fluorescent signals (Figure 6).
The tropism of BMSCs to the sites undergoing active cell
growth and differentiation makes them a smart delivery
system of therapeutic agents, especially in gene therapy of
cancer and severe destruction of tissues.
Discussion and conclusion
BMSCs have been used in the therapy of myocardial inf-
arction, osteogenesis imperfecta, syndrome of multiple
organ failure and rebuilding of haematopoietic function
after chemotherapy of breast cancer in pre-clinical and
clinical experiments [2-5]. In this report, we demonstrated
that systemically delivered BMSCs loaded with sFlt-1 gene
could preferentially home to tumor loci and induce anti-
angiogenesis as well as apoptosis of cancerous cells,
resulting in the decrease of lung metastases and prolonga-
tion of lifespan in mouse tumor model.
The BMSCs' capability of tissue repairing and homing has
been attracted great attention of scientists. Grove reported
that up to 20% of lung epithelium could be derived from
circulating BMSCs after lung injury, and a large portion of
lung damage could be repaired by forming entire alveoli.
Meantime, these adult stem cells could be effectively used
Anti-tumor effect in mouse LLC lung carcinoma modelFigure 3
Anti-tumor effect in mouse LLC lung carcinoma model. Female C57BL/6 mice received i.v. injection of 2×105 LLC cells 
in 100 μl of PBS. Treatment with 1×106 Adv-GFP-sFlt-1 infected BmSCs (, black rhombus), 1×106 Adv-GFP infected BmSCs 
(▪, black quadrilateral), 1×106 uninfected BmSCs (▲, black triangle) and 100 μl of 0.9% NaCl solution alone (●, black circular-
ity) were administered i.v. from tail vein. A significant increase of survival and decrease of metastases in sFlt-1-expressing 
BMSCs treated mice, compared with the controls (P < 0.05. By log-rank test), was found in this model.Page 6 of 10
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ability to differentiate into lung cells [21]. Darwin J Prock-
pop demonstrated that injured tissue create a milieu that
enhances homing, proliferation and differentiation of
BMSCs [7]. It has been found that there are high concen-
trations of fibroblast growth factor, transforming growth
factor β, platelet-derived growth factor, and epidermal
growth factor in injured tissue and in the microenviron-
ment of tumor, in which these facters are needed in the
process of homing, proliferation and differentiation of
BMSCs [22,23]. Therefore, we hypothesize that tissue
rebuilding in tumorigenesis, wound healing and fetal
development entitles the microenvironments the capabil-
ity of attracting the systemically administered BMSCs.
Suppression of VEGF by sFlt-1 adenoviruses administered
systemically was proved to contribute to inhibition of
tumor growth [12]. In our study, we employed BMSCs as
a gene vehicle loaded with sflt-1 recombinant adenovirus
for tumor therapy, and found that the BMSCs expressing
sFlt-1 preferentially homed to and survived in the tumor
loci where its strong anti-angiogenesis and anti-metastasis
effect has been observed. We also observed that BMSCs
expressing IL-12 induced a stronger antitumor effect than
administration with IL-12 adenoviruses alone (data not
shown). This vehicle may be useful and effective in tumor
gene therapy for four reasons. Firstly, the BMSCs after ex
vivo administration may survive for hundreds of days,
which enable them to offer a relatively long effect for
chronic diseases [24]. Secondly, the capacity of BMSCs
homing to tumor sites and protecting viruses against the
immune surveillance would strengthen the effect of
recombinant adenovirus gene therapy, which is unsatis-
factory when systemically administered alone because of
nonspecific distribution and serious hepatotoxicity
[11,25]. Thirdly, the lower immunogenicity, which is the
result of low expression of MHC and costimulatory mole-
cules, enables BMSCs advantageous for allogeneic or
Evaluation of anti-angiogenetic effect by CD31 immunohistochemistry and alginate assayFig re 4
Evaluation of anti-angiogenetic effect by CD31 immunohistochemistry and alginate assay. Sections of frozen 
CT26 tumor tissues obtained from mice treated with sFlt-1-bearing BMSCs, GFP-expressing BMSCs, unmodified BmSCs and 
0.9% NaCl solution were stained with CD31 antibody and Peroxidase-DAB (Figure 4-A). Vessel density was determined by 
counting the number of microvessels per high-power field (×200) in sections. (Figure4-B). Alginate beads containing different 
ratio of sFlt-1-bearing BMSCs and LLC (1/10, 1/100, 1/1000, LLC only) were implanted subcutaneously into C57BL/6 mice. 
Three weeks later, beads were surgically removed, and FITC-dextran was quantified. FITC-dextran uptake decrease and pho-
tograph of alginate implants showed the reduction of vascularization in beads containing relatively more sFlt-1-expressing 
BMSCs. (Figure4-C and D). Alginate beads containing MethA, BMSCs and mixture of both with ratio of 1/10 were prepared. 
Beads-MethA and beads-mixture were served as positive and negative controls. The third team of mice was implanted with 
two different beads containing MethA or BMSCs respectively in different sites of mice, which served as systemic sFlt-1 model 
to show the non-targeted effect of viruses. The fourth team of mice was implanted with beads containing MethA and hence 
injected intravenously with BMSCs in the same number of the former team, which served as local sFlt-1 model to show the tar-
geted effect of viruses loaded in BMSCs. Compared with the controls, the effect of systemic production of sFlt-1 was weaker 
than local one. (Figure 4-E and F).Page 7 of 10
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expanded in vitro and to be genetically modified, which
means convenience and cost effectiveness in the future
preclinical or clinical applications.
However, in the experiments performed by our lab (data
not shown) and others, the naive BMSCs seemed to pro-
mote growth of tumors. On the other hand, Aarif reported
that mesenchymal stem cells injected intravenously
homed to neoplasm and potently inhibited tumor growth
in Kaposi sarcoma model [27]. The relationship between
the stem cells and the cancer cells may depend on the
microenvironment which is created by these two kinds of
cells and others [28-31]. Besides, the possible transforma-
tion and the consequent tumorigenesis of BMSCs them-
selves remains to be clarified. Jakub and his colleagues
reported that bone marrow-derived mesenchymal stem
cells showed cytogenetic aberrations after several passages
in vitro, which resulted in malignant lesions when infused
to secondary recipients [32,33]. All of these contradictions
indicated that the fate and effect of BMSCs on tumor
growth should be further investigated.
In conclusion, we demonstrated that BMSCs might be
employed as a promising vehicle for tumor gene therapy
which can effectively not only improve the concentration
of anticancer therapeutics in tumors, but also modify the
tumor microenvironment. However, the fate and effect on
tumor growth of BMSCs systemically administrated
should be further evaluated.
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Fluorescent in situ hybridizationigure 6
Fluorescent in situ hybridization. Frozen sections of lung 
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Y chromosome probe (STAR*FISH; Cambio, Cambridge, 
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were totally negative for fluorescent signals.Page 8 of 10
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